作者: Benque, B ; Santangelo, M T ; Schaefer, M ; Mostafaei, F. ; Gomes Lopes, D ; Jajcevic, D. ; Gomes Lopes, D. ; Jajcevic, D ; Lee, H G ; Doshi, P ; Schaefer, M. ; Lee, H.G. ; Benque, B. ; Mostafaei, F ; Khinast, J G ; Santangelo, M.T. ; Doshi, P. ; Khinast, J.G.

Bin blending is one of the main steps in pharmaceutical production processes. Commercial-scale production of expensive products typically does not allow to perform a large number of experiments in order to optimize the process. Alternatively, Discrete Element Method (DEM) simulations can be used to evaluate the powder behavior (flow and blending pattern) during blending, identify the risks (e.g., segregation), and provide solutions to mitigate them. In this work, DEM simulations are used to investigate the blending of two granulated powders in commercial-scale cone and cylindrical (hoop) blenders. The DEM contact model parameters were calibrated based on the experimental compression and ring shear tests for both granulated powders to mimic the bulk powder behavior in the simulations. The model's output was compared to the experiments in one of the blending cases. The blending efficiency in the cone blenders was evaluated considering the fill levels, the presence of baffles, the rotating directions, the filling order, and the bin sizes. Furthermore, for the hoop blenders, the effects of blender's angle, rotation speed, and filling order were addressed. The main findings of the work were that, in cone blenders, the blending can be improved by introducing baffles and changing in the rotational direction frequently. In hoop blenders, blending can be improved by increasing the inclination angle from the horizontal plane and the rotational speed.

2024-12-01·Acta Crystallographica Section B-Structural Science Crystal Engineering and Materials

The seventh blind test of crystal structure prediction: structure generation methods

Article

A seventh blind test of crystal structure prediction was organized by the Cambridge Crystallographic Data Centre featuring seven target systems of varying complexity: a silicon and iodine-containing molecule, a copper coordination complex, a near-rigid molecule, a cocrystal, a polymorphic small agrochemical, a highly flexible polymorphic drug candidate, and a polymorphic morpholine salt. In this first of two parts focusing on structure generation methods, many crystal structure prediction (CSP) methods performed well for the small but flexible agrochemical compound, successfully reproducing the experimentally observed crystal structures, while few groups were successful for the systems of higher complexity. A powder X-ray diffraction (PXRD) assisted exercise demonstrated the use of CSP in successfully determining a crystal structure from a low-quality PXRD pattern. The use of CSP in the prediction of likely cocrystal stoichiometry was also explored, demonstrating multiple possible approaches. Crystallographic disorder emerged as an important theme throughout the test as both a challenge for analysis and a major achievement where two groups blindly predicted the existence of disorder for the first time. Additionally, large-scale comparisons of the sets of predicted crystal structures also showed that some methods yield sets that largely contain the same crystal structures.

2024-12-01·Acta Crystallographica Section B-Structural Science Crystal Engineering and Materials

The seventh blind test of crystal structure prediction: structure ranking methods

Article

A seventh blind test of crystal structure prediction has been organized by the Cambridge Crystallographic Data Centre. The results are presented in two parts, with this second part focusing on methods for ranking crystal structures in order of stability. The exercise involved standardized sets of structures seeded from a range of structure generation methods. Participants from 22 groups applied several periodic DFT-D methods, machine learned potentials, force fields derived from empirical data or quantum chemical calculations, and various combinations of the above. In addition, one non-energy-based scoring function was used. Results showed that periodic DFT-D methods overall agreed with experimental data within expected error margins, while one machine learned model, applying system-specific AIMnet potentials, agreed with experiment in many cases demonstrating promise as an efficient alternative to DFT-based methods. For target XXXII, a consensus was reached across periodic DFT methods, with consistently high predicted energies of experimental forms relative to the global minimum (above 4 kJ mol−1 at both low and ambient temperatures) suggesting a more stable polymorph is likely not yet observed. The calculation of free energies at ambient temperatures offered improvement of predictions only in some cases (for targets XXVII and XXXI). Several avenues for future research have been suggested, highlighting the need for greater efficiency considering the vast amounts of resources utilized in many cases.

270

项与 Catalent, Inc. 相关的新闻（医药）

2025-02-20

·catalent.com

Catalent Announces New Board Appointments

Adds three new directors with deep expertise across biopharma and life sciences Somerset, NJ – February 20, 2025 — Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring the right balance of industry experience and fresh perspective to achieve the vision for Catalent’s next chapter.” “We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable,” said John Greisch, Chair of the Board. “We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.” The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company following the completion of the acquisition by Novo Holdings in December 2024. “On behalf of Novo Holdings, I am pleased to welcome our new Board members, said Jonathan Levy, Senior Partner, Novo Holdings. “Their diverse expertise and strategic insight will strengthen Catalent’s operations as an independent CDMO. We look forward to their contributions as we shape the company’s next chapter of growth and continued focus on improving the lives of patients worldwide.” The appointment of these new Board Directors is effective immediately and completes the Company’s updates to its Board, which is now comprised of 7 directors. Sue Mahony is a senior executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served in a variety of senior leadership positions at Eli Lilly and Company from 2000 to 2018, most recently as Senior Vice President and President of Lilly Oncology and a member of the executive committee of Eli Lilly. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen and Bristol Myers Squibb. She currently serves on the board of directors of Assembly Biosciences, Inc., Axsome Therapeutics, Inc. and Zymeworks, Inc., and she previously served on the board of directors of Horizon Therapeutics, plc and Vifor Pharma. Dr. Mahony received a BSc and a PhD from Aston University and an MBA from London Business School. Marie-France Tschudin is a global healthcare leader with 30 years of experience in the biotechnology and pharmaceutical industry. Until September 2023, Ms. Tschudin was President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG and a member of the Executive Committee. Before that, she held increasingly senior leadership positions, including President, Novartis Pharmaceuticals. Prior to joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. Ms. Tschudin started her career as a sales representative and then held a number of sales and marketing positions at Johnson & Johnson and Schering-Plough. Currently, she is a Board Director for AXA Group and Mars, Inc. Ms. Tschudin graduated with a Master of Business Administration from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University. Tim Walbert served as the Chairman, President and Chief Executive Officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he held various executive leadership positions across biotech and pharma companies, including at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic Humira. Mr. Walbert serves on the boards of directors of Century Therapeutics and Sagimet Biosciences, both public biotech companies, and Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), each private clinical-stage biotech companies. Mr. Walbert received a Bachelor of Arts in Business from Muhlenberg College in Allentown, PA and now serves as a member of the College’s Board of Trustees. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com. Media Contact: Laura Hortas +1(609) 240-7025 media@catalent.com

高管变更并购

2025-01-21

·catalent.com

Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.

New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience January 21 2025 – SOMERSET, NJ– Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications. Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’ upcoming trials in New Jersey, New York, and surrounding areas. Galapagos’ innovative decentralized manufacturing platform for cell therapies is designed to be deployed close to cancer treatment centers. This class of therapies has shown promising results in patients with NHL, even those who have failed with other therapies. By bringing the manufacturing process closer to patients, Galapagos’ platform has the potential to deliver fresh, fit, stem-like early memory cell therapy with a median vein-to-vein time of seven days, thereby avoiding cryopreservation and eliminating the need for bridging therapy. “Catalent is passionate about increasing patient access to life-changing cell therapies like those being developed by Galapagos,” said Delara Motlagh, at Vice President, Global Cell Therapy and Plasmid DNA at Catalent. “We are delighted by this collaboration to support Galapagos’ decentralized cell therapy approach to bring these pioneering treatments to more patients with certain aggressive forms of NHL in a median vein-to-vein time of seven days. With our highly experienced cell therapy team, state-of-the-art facility network, and central location, we enable timely delivery of these important therapies.” Financial terms of the agreement are not disclosed. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com. Galapagos is a biotechnology company with operations in the U.S. and Europe dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, Galapagos synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, Galapagos is committed to challenging the status quo and delivering results for patients, its employees, and its shareholders. Galapagos’ goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that its innovations reach those who need them most. For additional information, please visit www.glpg.com or follow the Company on LinkedIn or X.

细胞疗法免疫疗法引进/卖出

2025-01-18

·PRNewswire

Biologics Contract Development And Manufacturing Organization (CDMO) Market , 58% of Growth to Originate from North America, Technavio

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 13.7% during the forecast period.For comprehensive forecast and historic data on regions,market segments, customer landscape, and companies- Click for the snapshot of this report Continue Reading Technavio has announced its latest market research report titled Global Biologics Contract Development And Manufacturing Organization (CDMO) Market 2025-2029 Region Outlook North America Europe Asia Rest of World 1. North America - North America is estimated to contribute 58%. To the growth of the global market. The Biologics Contract Development And Manufacturing Organization (CDMO) Market report forecasts market growth by revenue at global, regional & country levels from 2017 to 2027. The US market holds a significant share in the North American Biologics Contract Development and Manufacturing Organization (CDMO) industry. Key factors contributing to this include the active involvement of the US government in reimbursing biologics, growing patient awareness regarding the benefits of biologic therapies, and an increasing prevalence of chronic diseases. Major players, such as AbbVie, Eli Lilly, Merck, Pfizer, and Amgen, headquartered in the US, offer a range of contract development and manufacturing solutions and advanced technology services. These vendors cater to both small and medium-sized pharmaceutical and biotechnology companies in the region, enabling their success through differentiated products and services.For more insights on North America's significant contribution along with the market share of rest of the regions and countries - Download a FREE Sample Segmentation Overview Type 1.1 Mammalian 1.2 Microbial Product Type 2.1 Biologics 2.2 Biosimilars Geography 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) Service Country US, Germany, Canada, France, China, UK, Japan, Italy, India, and South Korea 1.1 Fastest growing segment: The mammalian segment holds a significant share in the global biologics Contract Development and Manufacturing Organization (CDMO) market due to the increasing use of mammalian cells in producing therapeutic proteins. Mammalian cells, derived from mammalian tissue, are primarily used for growing animal cells in vitro. These cells include fibroblasts, epithelial cells, lymphocytes, and macrophages. Lymphocytes are found in the blood, while the rest are found in tissue. The rising application of mammalian cells in treating various diseases, particularly in producing human proteins with high therapeutic potential, such as tissue plasminogen activators, clotting factors, and erythropoietin, is a major factor driving market growth. Recombinant proteins from mammalian cells are used in therapeutics for conditions ranging from diabetes to cancer, transforming the healthcare landscape. Moreover, mammalian cell culture technology is widely used for producing vaccines in bulk, making it a significant revenue generator in the market. For instance, Catalent Inc.'s agreement with Spicona to develop a COVID-19 vaccine using its proprietary GPEx cell line development technology is a testament to this trend. Catalent offers comprehensive services, including mammalian cell line development, process development, process validation, formulation development, and drug substance manufacturing, from preclinical to commercial stages. These factors are expected to fuel the growth of the mammalian segment in the global biologics CDMO market during the forecast period.Get a glance at the market contribution of rest of the segments - Download a FREE Sample Report in minutes! Research Analysis The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production and development of large molecules, including biologics, biosimilars, monoclonal antibodies, and cancer therapies, for pharmaceutical clients. This market caters to various therapeutic areas such as chronic infectious diseases, diabetes, and oncology. Biologics CDMOs specialize in supply chain management, quality testing, and clinical services for small-molecule drugs and biopharmaceuticals. They employ advanced technologies like automation, software development, process engineering, and biology to ensure optimal production and development of these complex therapeutics. Tissue processing is also a critical aspect of biologics CDMOs, ensuring the highest quality standards are met for the final product. Market Overview The Biologics Contract Development and Manufacturing Organization (CDMO) market encompasses the production of biologics, including small molecules, large molecules, biosimilars, monoclonal antibodies, cancer therapies, and vaccines, using advanced technology and specialized expertise. The market caters to various disease landscapes, including infectious diseases, chronic conditions such as diabetes, and ageing-related diseases like myelosuppression, cardiotoxicity, and renal insufficiency. Biologics CDMOs offer clinical services, process engineering, automation, and software development to biopharmaceutical companies. The market includes niche CDMOs focusing on biologics segment, monoclonal segment, immunotherapy, plant-based expression systems, and novel therapies. The supply chain involves third-party logistic providers ensuring evidence-based practice and quality testing. The market also covers non-mammalian (microbial) production of recombinant proteins and vaccines, somatic cells, tissues, and biological molecules like nucleic acids, cell receptors, and metabolic illnesses. The biology behind these complex molecules requires a deep understanding of homeostatic processes and metabolism, including hepatic metabolism and renal excretion. The geriatric population and mental state are significant considerations, as well as potential side effects such as polypharmacy, allergies, and gene therapy.Start exploring market insights by Download a FREE Sample Report in minutes! Key Topics Covered: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Venodr Landscape 11 Vendor Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗

100 项与 Catalent, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Catalent, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年04月25日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床2期

临床3期

申请上市

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

枸橼酸他莫昔芬 ( ER )	非浸润性导管内癌更多	批准上市
烟酰胺 ( PARP1 )	糙皮病更多	批准上市
盐酸吡昔替尼 ( CSF-1R x FLT3 x c-Kit )	腱鞘巨细胞瘤更多	申请上市
硫酸瑞美吉泮 ( CGRP receptor )	偏头痛更多	申请上市
塞利尼索 ( XPO1 )	多发性骨髓瘤更多	申请上市